Karyopharm Therapeutics Inc. diskutieren
Karyopharm Therapeutics Inc.
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,54 €
-3,84 %
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target raised by analysts at Barclays PLC from $5.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $34.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Robert W. Baird from $42.00 to $25.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Robert W. Baird from $25.00 to $21.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $12.00 price target on the stock, down previously from $15.00.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Neueste Beiträge
Roth_Capital in Discuss Vicor Corp.